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Research on auditory processing in Parkinson’s disease (PD) has recently made
substantial progress. At present, evidence has been found for altered auditory processing
in the clinical stage of PD. The auditory alterations in PD have been demonstrated
with low-cost and non-invasive assessments that are already used in routine clinical
practice. Since auditory alterations have been reported early in disease progression,
it would be highly relevant to investigate whether auditory markers could be provided
in the prodromal stage of PD. In addition, auditory alterations in early stage PD might
be modulated by dopaminergic medication. Therefore, the aim of this review is (1)
to summarize the literature on auditory processing in PD with a specific focus on
the early disease stages, (2) to give future perspectives on which audiological and
electrophysiological measurements could be useful in the prodromal stage of PD and
(3) to assess the effect of dopaminergic medication on potential auditory markers in the
prodromal stage of PD.
Keywords: Parkinson’s disease, auditory processing, prodromal markers, audiometry, otoacoustic emissions,
dichotic listening, auditory reflexes, auditory evoked potentials
INTRODUCTION
Biomarker research in Parkinson’s disease (PD) covers the development and validation of diverse
clinical, biochemical, neuroimaging and genetic markers of pathological alterations, preferably in
the early preclinical and prodromal stages of PD when a clinical diagnosis is not yet possible (1, 2).
Valid and useful biomarkers potentially target a window of therapeutic opportunity in the early
stages of the pathological process before clinical signs and symptoms emerge. Currently, evidence
has been found for 16 prodromal markers in PD (3). Among these, non-motor symptoms are
specifically interesting since they often precede the characteristic motor deficits in PD (4, 5). The
non-motor symptoms in PD include, among others, autonomic dysfunctions, cognitive deficits,
depression, sleep disorders, and sensory-perceptual alterations (6–8).
Biomarkers are specifically beneficial when they are non-invasive, easy and relatively inexpensive
to administer, sufficiently available, and reliable (9, 10). These features seem explicitly present in
assessments related to auditory processing, ranging from audiological toward electrophysiological
measurements. At present, evidence has been found for altered auditory processing in the clinical
stage of PD. The alterations range from disturbances in the processing of basic acoustic features
toward the perception of affective and linguistic prosody (11, 12) and can be demonstrated with
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low-cost and non-invasive assessments that are already used
in routine clinical practice. Since auditory alterations have
also been reported in the early stages of PD, it would be
highly relevant to investigate whether auditory markers can be
found in the prodromal stage of PD. However, to date, no
studies have assessed the potential of auditory markers in the
prodromal stage of PD. In addition, auditory alterations might be
modulated by dopaminergic medication. As such, assessing the
effect of dopaminergic medication on auditory processing in the
prodromal and early stages of PD will be important to identify
pharmacological strategies to optimize auditory processing in
PD. Therefore, the aim of this review is (1) to summarize the
literature on auditory processing in PD with a specific focus
on the early disease stages, (2) to give future perspectives on
which audiological and electrophysiological measurements could
be useful in the prodromal stage of PD and (3) to assess the effect
of dopaminergic medication on potential auditory markers in the
prodromal stage of PD.
METHODS
A stepwise approach was followed to summarize the literature
on auditory processing in PD and to achieve the objectives of
the current review. First, a comprehensive literature search
was performed in four databases: MEDLINE (PubMed
interface), Embase (Embase.com interface), Web of Science
and The Cochrane Central Register of Controlled Trials
(CENTRAL Cochrane Library). The search strategy was
based on two separate search strategies for a systematic
review covering central auditory processing in parkinsonian
disorders and a systematic review covering the auditory
P3 in PD. Finally, to be able to provide a comprehensive
review on all auditory processing stages, elements related
to peripheral auditory processing were added that were not
covered by any of the two existing search strategies. The
search strategy included key terms related to PD on the
one hand (e.g., “Parkinson Disease,” parkinson∗), and key
terms related to auditory processing and its audiological and
electrophysiological measurements on the other hand (e.g.,
“Hearing Threshold,” “Auditory Perception,” “Evoked Potentials
Auditory, Brain Stem”). Only peer-reviewed articles in English
were retained.
Second, titles and abstracts were screened to identify relevant
studies. Subsequently, they were listed according to the type
of audiological or electrophysiological measurement. Of these
studies, Hoehn and Yahr (H&Y) staging (mean, SD, and range)
and disease duration (mean, SD, and range) of the patients with
PD who participated in the study, were determined. Articles were
considered as “early stage PD” when the patient characteristics
(of subgroups) met the following criteria: (1) all individual
participants were at H&Y stage < III, (2) mean group H&Y
stage was ≤ II, and (3) mean group disease duration was ≤ 6.0
years (13–15). The literature on auditory processing in all clinical
disease stages of PD was synthesized for each type of audiological
or electrophysiological measurement. Detailed outcomes and
results of the systematic review are published elsewhere (16).
Finally, a specific focus was given on the results of “early stage
PD” studies.
AUDIOLOGICAL MEASUREMENTS
Peripheral Auditory Tests
Pure-Tone Audiometry
Pure-tone audiometry has been considered a gold standard in
the audiological examination to evaluate hearing sensitivity.
Based on the participant’s response to pure-tone stimuli, hearing
thresholds are measured at a frequency range of 0.250–8 kHz.
The clinical aim of pure-tone audiometry is to determine the
type, degree and configuration of the patient’s hearing loss. In
study groups with older participants, presbycusis or progressive
bilateral hearing loss related to aging can be expected. Indeed,
a high-frequency age-related hearing impairment has been
shown in studies that used pure-tone audiometry to evaluate
the hearing sensitivity of patients with PD and age-matched
control participants (HCs). On the one hand, multiple studies
have demonstrated the same sloping audiometric pattern in
patients with PD compared to HCs, consistent with the presence
of an age-related hearing loss (17–20). These studies did not
find significant differences between patients with PD and HCs
regarding pure-tone hearing thresholds. On the other hand,
higher pure-tone hearing thresholds in patients with PD have
been reported by other research groups in the middle to high
frequency range (1.5–8 kHz) (21–28). The differences between
study results may be influenced by the approach chosen to
analyze the data (e.g., categorical vs. continuous data-analysis,
consideration of confounding variables, correction for multiple
comparisons). So, although a sensorineural hearing loss has been
shown in patients with PD, it remains unclear whether hearing
thresholds as measured with pure-tone audiometry are indeed
higher in patients with PD compared to age-matched HCs.
Regarding early stage PD, Pisani et al. (23) carried out
pure-tone audiometry to investigate the effect of dopaminergic
treatment on hearing sensitivity in 11 previously untreated
de-novo patients with PD. In the drug-naïve condition, a
significantly higher hearing threshold was found at 2 kHz in
the PD group compared to age-matched HCs. Following the
initiation of dopaminergic treatment for a period between 1 and
3 months, pure-tone hearing thresholds remained unchanged in
de-novo patients with PD. In the study of Yylmaz et al. (28),
higher hearing thresholds at 4 and 8 kHz were demonstrated
in patients with PD at H&Y stage II. However, in their study,
patients with PD were on average 6.1 years older compared to
the HC group. In a recent study, Scarpa et al. (29) also reported
higher hearing thresholds at 4 to 8 kHz in patients with PD
with an average disease duration of 4.8 year compared to HCs.
However, the authors suggested that increased hearing thresholds
in the high frequency range may not be a distinct feature of PD,
as patients with multiple system atrophy demonstrated a similar
sloping audiometric pattern in the same study.
Speech Audiometry
In addition to pure-tone audiometry, speech audiometry is
also routinely administered in audiological practice. Speech
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audiometry compromises many tests, varying according to
the type of speech material, task demands, response format
and the presence of background noise. Speech recognition
scores are calculated as the percentage of correct responses
for each stimulus presentation level (relative to the noise).
The resulting performance-intensity function is characterized in
terms of its configuration and the level at which speech can
be correctly identified half of the time [Speech Recognition
Threshold, SRT (30)]. The clinical aim of speech audiometry
is differentiating cochlear from retrocochlear lesions. Regarding
speech audiometry in silence, two studies have found normal
speech recognition scores in patients with PD compared to age-
matched HCs (17, 31). In contrast, Vitale et al. (26) found a
significantly higher SRT in patients with PD compared to age-
matched HCs. In their study, significantly more patients with
PD demonstrated a performance-intensity function that was
suggestive of a cochlear dysfunction. The differences between
study results are likely due to differences regarding hearing
sensitivity of patients with PD and HCs, as measured with
pure-tone audiometry. More specifically, if pure-tone hearing
thresholds are increased compared to HCs, as was the case
for patients with PD in Vitale et al. (26), abnormal speech
recognition scores can be expected. Regarding speech audiometry
in noise, no significant differences regarding speech recognition
scores were reported between medicated patients with PD and
HCs (17, 22). Interestingly, a modulatory effect of dopaminergic
medication state was found on both speech audiometry in silence
and in noise (17). The same patients with PD performed slightly
better when they were tested without medication compared to
when they were tested with medication.
No study has specifically focused on speech audiometry in
early stage PD. As speech audiometry generally demonstrates
normal results in patients with PD at more advanced disease
stages, no differences are expected regarding speech perception
in early stage patients with PD, provided that pure-tone hearing
thresholds are within the normal range accounting for age
and gender.
Otoacoustic Emissions
Otoacoustic emissions (OAEs) provide a non-invasive and
objective measurement of outer hair cell (OHC) functioning.
OAEs are sounds of cochlear origin, which are recorded with a
microphone probe fitted in the ear canal. The sounds originate
from vibrations of the eardrum that are transmitted backwards
from the cochlea through the middle ear. These vibrations are
caused by the motion of OHCs as they respond to auditory
stimulation (32) (Figure 1). There are two widely used OAE
measurements: transient evoked OAEs (TEOAEs) and distortion
product OAEs (DPOAEs). Robust TEOAE responses are evoked
by click stimuli around 80 dB SPL. Although clicks are broadband
signals, TEOAEs give a frequency specific indication of OHC
functioning between 1 and 4 kHz. On the other hand, DPOAEs
are evoked using pairs of pure tones at a lower stimulus level,
usually 65/55 dB SPL. DPOAEs offer a wider frequency range
than TEOAE measurements with less sensitivity to minor and
subclinical alterations in adults. Similar to hearing thresholds,
age-related changes in the OAE response can be expected
(34). In routine audiological practice, it is the presence of
a detectable OAE response to a particular stimulus that is
important. Frequencies at which hearing thresholds exceed 35
dB HL typically show an absent OAE response. Hence, the
presence of OAE decreases with increasing age, especially at
higher frequencies. In patients with PD, the presence of TEOAE
and DPOAE responses did not differ significantly from HCs (17,
20). Additionally, for research purposes, the response amplitudes
of OAEs can be used for group comparisons. Regarding TEOAEs,
two studies reported lower response amplitudes in medicated
patients with PD compared to HCs (18, 23). In contrast, De
Keyser et al. (17) found no significant differences regarding
TEOAE response amplitudes between medicated patients with
PD and age-matched HCs. Regarding DPOAEs, similar response
amplitudes were found between medicated patients with PD
compared to HCs (17, 23). Nevertheless, a modulatory effect of
dopaminergic medication on the OAE response amplitudes has
been found. OAE response amplitudes were higher when the
same patients with PD were tested without their medication (17).
This result corroborates with the study of Lopes et al. (19), who
found higher DPOAE response amplitudes in patients with PD
receiving low daily doses of dopaminergic medication compared
to patients receiving higher doses.
Moreover, OAEs can be used to examine the integrity
of the efferent auditory pathways by applying contralateral
acoustic stimulation (CAS). In normally hearing individuals,
OAE response amplitudes decrease during CAS, because acoustic
stimulation activates the medial olivocochlear (MOC) efferent
system, which in turn has an inhibitory effect on OHC motility.
This inhibitory effect is termed efferent suppression (ES).
Generally, if CAS fails to reduce the OAE response amplitudes by
1 dB or more, ES is described as abnormal (35). In PD, abnormal
ES of TEOAEs has been reported by Di Mauro et al. (18). In this
study, “increased TEOAE response amplitudes during CAS” were
described in patients with PD. It is, however, unclear whether
response amplitudes were increased compared toHCs or whether
they were increased compared to response amplitudes of the
same patients, but in the absence of CAS. In any case, this result
indicates decreased to absent ES of TEOAEs in patients with
PD, which may support the involvement of the efferent auditory
pathway in the pathology of PD. Regarding ES of DPOAEs, both
patients and HCs generally demonstrated adequate reduction
during CAS and no significant difference could be demonstrated
regarding the amount of ES between patients with PD and
HCs (19). Nevertheless, a modulatory effect of dopaminergic
medication dosage has been found on ES in patients with PD. ES
of DPOAEs was higher in patients receiving higher daily doses
of dopaminergic medication compared to those receiving lower
doses, albeit only statistically significant at 2 and 3 kHz.
Regarding early stage PD, only Pisani et al. (23) evaluated
OAEs in 11 de-novo patients with PD. In their study, OAEs
were administered to investigate possible alterations of cochlear
functioning after initiating dopaminergic treatment in previously
untreated patients with PD. In the drug-naïve condition, lower
TEOAE and DPOAE response amplitudes were found in
patients with PD compared to HCs. Following the initiation
of dopaminergic treatment for a period between 1 and 3
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FIGURE 1 | A schematic representation of the structures that are involved in the generation and suppression of OAEs. The dashed and full lines represent the afferent
and efferent auditory pathways, respectively. Sound enters the ipsilateral cochlea through the middle ear and is analyzed along the length of the cochlea. Outer hair
cells amplify the motion of the basilar membrane. Vibratory energy is transmitted backwards through the middle ear and produces the OAEs. The medial (MOC) and
the lateral olivocochlear (LOC) system provide efferent innervation to the cochlea. The MOC system is stimulated by crossed afferents and projects to the ipsilateral
and contralateral cochlea. MOC efferents have an inhibitory effect on OHC activity. Therefore, acoustic stimulation of the contralateral ear leads to a reduction of the
response amplitudes of OAEs (i.e., efferent suppression). Based on Guinan (33).
months, TEOAEs remained unchanged, while DPOAE response
amplitudes significantly increased compared to the drug-naïve
condition, resulting in an outcome more similar to HCs.
Auditory Reflexes
Stapedial reflex testing is usually administered as part of acoustic
immittance measurements (tympanometry). When presented
with a sufficiently high-intensity stimulus, the stapedial muscles
contract bilaterally and stiffen the ossicular chain, thus decreasing
middle-ear admittance (36). The stapedial reflex depends on
the intact function of the entire reflex arc, including the
middle and inner ear (sensory receptors), the cochlear nerve
(afferent neurons), the lower brainstem (interneurons) and the
facial nerve (efferent neurons). The stapedial reflex can be
measured both ispilaterally and contralaterally. The specific site
of lesion is determined by comparing the stapedial reflexes
in response to ipsilateral vs. contralateral acoustic stimulation.
The clinically most relevant outcome of stapedial reflex testing
is the acoustic reflex threshold (ART) or the lowest intensity
at which a minimal change of admittance is measurable. The
ART generally ranges between 70 and 100 dB HL for pure
tones. In the study of Murofushi et al. (37), patients with PD
and HCs demonstrated an ART that was well within normal
limits, although the ART of patients with PD was significantly
lower compared to HCs. For research purposes, a series of
latency measures can be extracted from the stapedial reflex. In
patients with PD, the latency between stimulus onset and the
time at which the stapedial reflex reaches 50% of its maximal
amplitude was significantly prolonged compared to HCs (37).
In addition, following cessation of the stimulus, patients with
PD demonstrated a significantly longer latency for the amplitude
to decrease to 50% of its maximal amplitude compared to
HCs. These latency measures did not differ significantly between
patients with PD taking dopaminergic medication and those who
were not taking dopaminergic medication.
An auditory reflex that is also elicited by a high-intensity
stimulus, is the auditory startle response (ASR). The ASR is a
generalized motor response produced reflexively in response to
a sudden, loud sound that results in a quick, usually observable
movement. It is generally believed to be a brainstem reflex
that originates in the pontine reticular formation, which is
innervated by auditory afferents through the cochlear nucleus
and connects with efferents that supply the target muscles,
including the bulbar reticular tract, the reticulospinal tract,
spinal interneurons and cranial and spinal motor neurons (38).
The muscular activity of interest, such as the ocular, facial,
neck, upper, and lower extremity muscles, can be objectively
measured with electromyography (EMG). A variety of response
parameters can be extracted from the EMG response, including
the amplitude, latency, duration and habituation of the ASR.
In the auditory field, the ASR is known as a cursory test for
hearing sensitivity (39). In addition, an increased ASR has been
associated with reduced sound tolerance (40), hyperacusis (41)
and tinnitus (42). In PD, the ASR has primarily been studied
as a potential marker for the differentiation from patients with
progressive supranuclear palsy. The neural loss in this type of
parkinsonism specifically involves the cholinergic neurons of
the pontine reticular formation, including those involved in the
ASR (43). In patients with PD, studies have generally found
present ASRs demonstrating a normal amplitude, duration and
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habituation compared to HCs (43–46). Regarding the onset
latency of the ASR, both prolonged (45, 46), as well as shortened
latencies (44) have been reported in patients with PD, depending
on the muscular activity of interest. Prolonged latency measures
have been related to withdrawal of facilitatory input to brainstem
centers from the basal ganglia (45, 46). No modulatory effect of
dopaminergic medication has been found on the ASR in patients
with PD (45, 46).
No study has specifically focused on auditory reflexes in early
stage PD. While auditory reflexes may be able to differentiate
between patients with PD and progressive supranuclear palsy in
the clinical stages of PD, it appears unlikely that abnormalities
regarding the latency of auditory reflexes will be able to reliably
detect early stage PD. Furthermore, latency abnormalities have
also been reported in other parkinsonian disorders, such as
multiple system atrophy (44, 47) and dementia with Lewy bodies
(44). These findings suggest that auditory reflex testing has
limited potential to discriminate PD from atypical parkinsonian
disorders. In addition, auditory reflexes are mediated by multiple
neural circuits and abnormal or absent responses do not
necessarily comprise a problem with auditory function.
Central Auditory Tests
Psychoacoustic Experiments Assessing, Pitch,
Loudness, Temporal Perception
Psychoacoustic experiments are concerned with the relationship
between the physical characteristics of an auditory stimulus and
their perceptual attributes (48). In PD, psychoacoustic research
has been used to examine the perception of basic acoustic
features (frequency, intensity, duration), i.e., pitch, loudness
and duration. The methods used in these studies vary greatly
according to stimulus type (verbal and non-verbal stimuli)
and task demands (detection, discrimination, categorization
and estimation). Regarding psychoacoustic experiments using
pure-tone stimuli, patients with PD demonstrated increased
discrimination thresholds for duration (49–52) and frequency
[albeit not statistically significant (51, 53)] compared to HCs.
Likewise, patients with PD had more difficulty at discriminating
perceptually small acoustic differences compared to HCs (12,
54). On the other hand, when perceptually larger differences
were used to assess auditory discrimination, no significant
differences could be found between patients with PD and HCs
(12, 53, 55). Auditory categorization and estimation tasks of
intensity and duration have generally not found significant
differences between patients with PD and HCs (53, 56–60).
Regarding psychoacoustic experiments using speech stimuli,
multiple studies have found abnormal perception of speech
intensity (61–64). More specifically, patients with PD appear
to overestimate the intensity of less intense speech and to
underestimate the intensity of more intense speech.
Only a few studies have administered psychoacoustic
experiments in patients with early stage PD. Breitenstein et al.
(54) evaluated duration and frequency discrimination to assess
the contribution of altered auditory perception to the disturbed
perception of prosody. In this study, a subgroup of six recently
diagnosed (on average 16.2 months) patients with PD were
included who had not yet received dopaminergic treatment. No
significant differences were found between early stage patients
with PD and age-matched HCs for the discrimination of pure
tones differing either with respect to frequency or duration.
In the study of Lopes et al. (20), patients with PD were also
divided into two subgroups regarding disease stage. As such,
34 patients with PD at H&Y stage I to II were included in the
early stage PD group. The Duration Pattern Test demonstrated
that early stage patients with PD had more difficulty to identify
the order of a sequence of three pure tones (e.g., long—short—
short) compared to HCs. This difference was, however, only
significant in a subgroup of patients with PD aged 42–64 years,
but not in older patients with PD. In the same study, the Gap-
in-Noise test did not reveal significant differences between early
stage patients with PD and HCs, as the duration detection
threshold for silent intervals embedded in ongoing noise was
similar in both groups. Likewise, patients in the more advanced
PD group did not differ significantly from HCs. Lastly, Graber
et al. (65) examined whether altered duration perception in PD
affects their categorical perception of phonemes. They included
nine early stage patients with PD, who were all at H&Y stage
I to II and had a maximum disease duration of 6.0 years.
The word-medial occlusion length and voice onset time were
varied in order to create a continuum between two unambiguous
endpoints, the minimal word pairs boden/boten and dick/tick,
respectively. For both manipulations, early stage patients with
PD made, on average, similar categorical decisions compared to
age-matched HCs. Three patients, however, perceived “boden”
throughout the whole continuum and needed a considerably
longer occlusion interval to perceive the minimal pair cognate
“boten.” This result could not be readily explained by differences
regarding disease staging (as all patients were in an early disease
stage), age, dopaminergic medication state, nor verbal intellectual
abilities. Altogether, current research has found no evidence for
alterations regarding the perception of basic acoustic features in
early stage PD. In more advanced PD, psychoacoustic studies
suggest that (ab)normal auditory perception is highly dependent
on the paradigm that is used (16). More specific, tasks that probe
the lower limits of the ability to detect and discriminate auditory
changes have demonstrated abnormal results in PD. Further
research might indicate whether more complex psychoacoustic
experiments could be suitable to differentiate early stage patients
with PD from HCs.
Dichotic Listening Tests
Dichotic listening tests are among the most widely used
behavioral tests to assess central auditory processing. Dichotic
listening refers to listening to different speech stimuli presented
to each ear simultaneously or in an overlapping manner (66).
A great variation of dichotic listening tests exists, varying with
regards to the speech stimuli (i.e., consonant-vowels, digits,
words or sentences), as well as the response condition. Two types
of response conditions can be used that engage the integration
or segregation of binaural auditory input, respectively (30).
Namely one condition that requires divided attention (free recall
condition) and one condition that requires selective attention
(right/left ear recall condition). Multiple studies have addressed
dichotic listening in a divided attention paradigm in patients
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with PD. Overall, these studies did not find significant group
differences between patients with PD and HCs (20, 22, 67, 68).
Only Richardson et al. (69) reported that a substantial part
of patients with PD demonstrated abnormal dichotic listening
compared to normative values.
In agreement with research in more advanced patients with
PD, Lopes et al. (20) found no alterations regarding dichotic
listening in a divided attention paradigm in early stage PD. In
their study, a subgroup of 34 patients with PD at H&Y stage I to II
did not differ significantly from HCs regarding the percentage of
correctly repeated digits. On the other hand, Sharpe (70, 71) has
evaluated dichotic listening in a more complex task to examine
(auditory) attentional deficits in patients with early stage PD. The
task consisted of dichotically presented word pairs containing the
target word or a phonemic distractor paired with a phonetically
unrelated word. Two studies used this task in either a divided
attention paradigm (71) or a selective attention paradigm (70).
In both studies, 14 patients with PD were included that were
at H&Y stage I to II and had a mean disease duration of
4.2 years. In the divided attention paradigm, patients with PD
discriminated significantly less target words compared to HCs.
In the selective attention paradigm, patients with PD and HCs
did not differ significantly regarding the discrimination of target
words in the to-be attended ear, considering the percentage of
ipsilateral responses to targets and distractors was similar in both
groups. Nevertheless, the author suggested that “patients with PD
were more prone to the interference of phonemic distractors,”
as patients with PD made “more contralateral responses to false
positive errors in the unattended ear.” In sum, most studies point
to a preserved performance in conventional dichotic listening
tests that probe divided auditory attention in all clinical stages
of PD, including the earliest disease stage. Nevertheless, more
complex dichotic listening tests may be able to differentiate early
stage patients with PD from HCs.
Binaural Interaction Procedures
Binaural interaction tests depend upon intact binaural processing
in the central auditory nervous system. Binaural processing
enables sound localization and lateralization, and improves
speech perception in adverse listening conditions. These tests
require the combination of complementary input presented to
both ears simultaneously, synthesizing intensity, temporal, and
spectral differences of otherwise identical stimuli (66). Binaural
interaction is presumed to occur in the brainstem (72). Hence,
these tests are thought to be sensitive to brainstem lesions. A
great variation of procedures can be used to evaluate binaural
interaction. Some of these tests may be useful to demonstrate
alterations regarding binaural processing in patients with PD
compared to HCs, including auditory lateralization (73) and
spatial listening tasks (22). In contrast, binaural masking level
difference tasks, that assess the ability to detect a tonal stimulus
in noise when the binaural signal-to-noise phase relationships
are altered, show no significant differences in patients with PD
compared to HCs (22).
No study has specifically focused on binaural auditory
processing in early stage PD.
Summary: Audiological Measurements
in PD
A summary of study findings regarding audiological
measurements in early stage patients with PD can be found
in Table 1. Altogether, auditory research in PD has found
alterations at all clinical disease stages using audiological
measurements associated with both peripheral and central
auditory processing. Unfortunately, to date, few studies have
specifically examined auditory processing in early stage PD.
Nevertheless, these studies suggest an involvement of the
auditory system early in disease progression. At the peripheral
level, three studies using subjective pure-tone audiometry
provided evidence that hearing thresholds in the middle to high
frequency range may be increased in early stage patients with
PD. In one of these studies, hearing thresholds did not change
following initiation with dopaminergic medication. Likewise,
objective OAE measurements demonstrated altered auditory
processing in early stage patients with PD, based on decreased
response amplitudes compared to HCs. Moreover, OAE response
amplitudes increased following initiation with dopaminergic
medication. Although OAEs are generally associated with
cochlear dysfunction, alterations may also indicate a dysfunction
of the efferent control of the OHCs by the MOC system. In this
regard, decreased ES of OAEs has been reported in patients with
more advanced PD. However, further research is warranted into
early alterations of the MOC system in PD, assessed using OAE
and ES measurements. Especially since an involvement of the
MOC system can be hypothesized during the early stages of
PD pathology involving the lower brainstem (75). Behavioral
measurements associated with central auditory processing in PD
demonstrated that results are generally highly dependent on the
paradigm that is being used. Therefore, experiments may have
to be tailored toward specific hypotheses regarding early stage
PD. For example, more complex tasks that stress the auditory
system to a higher level, such as adaptive measurements of
auditory discrimination and adapted tasks of dichotic listening,
may be more suitable to discriminate patients with early stage
PD from HCs.
ELECTROPHYSIOLOGICAL
MEASUREMENTS
Short Latency Auditory Evoked Potentials
Short latency auditory evoked potentials (AEPs), better known as
the auditory brainstem response (ABR), are routinely evaluated
in audiological practice. In adults, the peak latency and interpeak
latency (IPL) of the ABR are typically used in the diagnosis of
retrocochlear pathologies, such as vestibular schwannoma and
lesions of the brainstem. The ABR consists of seven distinct
waves that occur within 10ms and is recorded with a high-
intensity transient acoustic stimulus, most commonly a click. The
auditory nerve and auditory nuclei located in the brainstem are
the major structures involved in the generation of the ABR. Each
wave, labeled using Roman numerals, reflects the synchronous
firing of different auditory cell populations. As such, waves I
and II are derived from the distal and proximal regions of the
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TABLE 1 | Summary of study findings regarding audiological measurements in early stage patients with Parkinson’s disease.
Audiological measurements Description Early stage PD
studies
Study findings Effect of
dopaminergic
medication
Strengths/limitations
Peripheral auditory tests
i. Pure-tone audiometry Measurement of
hearing sensitivity to
pure-tone stimuli
(23*, 28, 74) Higher hearing
thresholds at 2, 4, 6,
and 8 kHz
No effect was found + Gold standard in audiology,
standardized clinical method
– Low specificity (high prevalence of
high-frequency hearing impairment in
the general elderly population),
subjectivity
ii. Speech audiometry Measurement of
speech recognition
No early stage PD
studies
− − + Information on functional auditory
status
– Time consuming, influence of
cognitive factors, low sensitivity (most
patients in the clinical PD stage
demonstrate no
abnormalities), subjectivity
iii. Otoacoustic emissions Measurement of outer
hair cell cochlear
functioning
(23)* Lower TEOAE and
DPOAE response
amplitudes in de-novo
patients with PD
DPOAE response
amplitudes increased
+ Objectivity, direct link to
neurotransmission, time efficiency,
standardized clinical method, ability to
detect subclinical auditory alterations
– Low specificity (reduction of OAE
response amplitude in the general
elderly population), absent response
at hearing thresholds >35 dB HL
iv. Auditory reflexes Measurement of
stapedial reflex or
auditory startle
response
No early stage PD
studies
− − + Objectivity
– Low specificity (atypical
parkinsonian disorders demonstrate
abnormal auditory reflexes as well)
Central auditory tests
i. Psychoacoustic tests Measurement of
acoustic feature
perception
(20, 54, 65) No difference in
gap-in-noise detection,
frequency and duration
discrimination,
phoneme
categorization, altered
duration pattern
recognition
− – Time consuming, subjectivity, no
standardized clinical method, low
sensitivity (most patients with early
stage PD demonstrate no
abnormalities)
ii. Dichotic listening tests Measurement of the
integration or
segregation of binaural
auditory input
(20, 70, 71) Divided attention
paradigm: no difference
in digit repetition,
altered target word
discrimination in a
complex task
Selective attention
paradigm: no difference
− + Sensitized test (high level of
difficulty)
– Influence of cognitive factors, no
standardized clinical
method, subjectivity
iii. Binaural hearing tests Measurement of the
integration of intensity,
temporal, or spectral
differences of otherwise
identical stimuli
No early stage PD
studies
− − – No standardized clinical method,
subjectivity
Study findings indicate the results of audiological measurements in early stage patients with Parkinson’s disease (PD) compared to healthy control participants. Studies investigating
the effect of dopaminergic medication on auditory processing in early stage PD are indicated with an asterisk (*). The main strengths and/or limitations whether or not to incorporate the
audiological measurements into a prodromal auditory marker protocol for PD are given. PD, Parkinson’s disease.
auditory nerve as it enters the brainstem, while waves III to
VII are generated from successively higher brainstem structures
(76). The components following wave V show large intersubject
and within-subject variability and are, therefore, less useful for
research purposes. Studies on age-related changes of the ABR
have reported only slight changes regarding wave latencies and
IPLs. Generally, prolongations appear to be limited to the early
waves I to III, suggesting that age primarily affects peripheral
auditory nerve transmission (77, 78). As increasing evidence
suggests that PD initially affects the brainstem and follows a
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predominant upwards course (75), considerable attention has
been devoted to measures of brainstem functioning in PD, such
as the ABR. On the one hand, various studies have reported
normal latency measures in patients with PD compared HCs
(25, 27, 79, 80). On the other hand, multiple other studies have
reported prolonged latencies for the centrally generated waves
III to V in patients with PD compared to age-matched HCs (21,
24, 28, 81–84). In addition, prolonged IPLs have also frequently
been found in patients with PD compared to HCs for waves III-V,
and I-V. The differences between study results cannot be readily
explained by methodological differences or patient variables. At
present, although there is some evidence that suggests abnormal
ABR results, experimental support for altered auditory brainstem
processing in patients with PD is inconsistent.
Regarding early stage PD, two studies have investigated the
ABR in early stage patients with PD. Karayanidis et al. (79)
administered ABR testing in 16 patients with PD (to ensure that
the main outcome of their study, which was centered around the
long latency event-related potentials (ERPs), was not confounded
by differences in auditory brainstem processing). All patients had
a relatively recent diagnosis (on average 3.0 years) and “most of
themwere at H&Y stages I or II”. Compared to age-matchedHCs,
patients with PD exhibited a non-significant prolongation of the
IPL between wave I and III. No significant group differences were
found for the IPL between wave I and V and wave V latency. In
contrast, Yylmaz et al. (28) found significantly prolonged IPLs
between wave I and V and wave V latencies in 20 patients with
PD at H&Y stage II compared to HCs. However, in their study,
patients with PD were on average 6.1 years older compared to
the HC group. The result of Yylmaz et al. (28) may indicate a
similar pattern of centrally located ABR abnormalities found in
more advanced patients with PD. Nonetheless, further research
is warranted.
Middle Latency Auditory Evoked Potentials
Following the ABR, middle latency AEPs are generated between
10 and 50ms after the onset of a transient auditory stimulus,
such as a tone burst or a click. Middle latency AEPs are not
routinely administered in audiological practice, as they are highly
sensitive to the participant’s attention and state of arousal,
as well as to several recording parameters, especially stimulus
presentation rate (85–87). However, when these variables are
adequately controlled for, middle latency AEPs can be useful
to assess the functional integrity of the auditory pathways and
to localize lesions at the thalamocortical and primary auditory
cortex levels (87). Traditionally, four positive and three negative
peaks are included in the middle latency AEPs, namely V,
N0, P0, Na, Pa, Nb, and P50. In patients with PD, P50 is
the most frequently studied middle latency AEP. When using
a sufficiently low stimulus presentation rate, no abnormalities
regarding P50 amplitude or latency appear evident in patients
with PD compared to HCs (88–91). On the other hand, higher
presentation rates may lead to P50 being absent or having a
prolonged latency in a substantial part of patients with PD
(92). In addition to stimulus trains, the P50 can be evoked
by pairs of stimuli. The paired-stimulus paradigm is useful for
investigating auditory gating. Auditory gating represents the
central auditory nervous system’s ability to suppress irrelevant
auditory stimuli (93). When two identical stimuli are presented
in a paired-stimulus paradigm, P50 to the second stimulus is
inhibited relatively to the first stimulus in HCs. Patients with
PD exhibited significantly less inhibition of P50 to the second
stimulus compared to age-matched HCs, suggesting diminished
auditory gating in PD (90, 91). All patients were in rather
advanced disease stages (H&Y ranging between III and V).
Interestingly, when patients were divided according to disease
stage, both studies found that patients at H&Y stage III did not
differ significantly from HCs regarding P50 inhibition, and that
abnormalities were limited to patients with PD at H&Y stages
IV and V.
No study has specifically focused on the middle latency AEPs
in early stage PD. It may be interesting to investigate middle
latency AEPs in early stage patients with PD in response to high
stimulus presentation rates, as abnormalities were found in a
large sample of patients with PD (n = 46) that varied greatly
regarding H&Y disease stage (range I to IV) and disease duration
(range 1–24 years) (92). Regarding auditory gating, based on
the studies of Teo et al. (90, 91), it appears unlikely that P50
inhibition would be able to discriminate early stage patients with
PD from HCs, given the finding that only patients in the most
advanced disease stages differed significantly from HCs in terms
of P50 inhibition.
Long Latency Auditory Evoked Potentials
P1-N1-P2 Complex
The auditory P1-N1-P2 complex represents an exogenous
stimulus-related response associated with sound detection (94,
95). The ERP-waveform consists of three deflections, namely P1,
N1, and P2 that reach their maximal amplitude at around 50,
100, and 160ms respectively. The first component, P1, has been
considered to overlap -to some extent- with the P50 studied
as a middle latency AEP. The auditory P1-N1-P2 complex
can be evoked in both passive or active listening conditions
based on different stimulus paradigms, such as stimulus trains,
paired-stimulus paradigms or oddball paradigms. In audiological
practice, the P1-N1-P2 complex has been most commonly
investigated as an objective counterpart of behavioral audiometry
to estimate a participant’s hearing thresholds. On average, the
P1-N1-P2 complex can be found at 10 dB above the behavioral
hearing threshold (96). From a broader point of view, the
outcome of the P1-N1-P2 waveform highly depends on the
acoustic characteristics of the stimulus, such as frequency,
intensity, duration, and location (94). Based on the majority
of studies that used an auditory oddball paradigm, no altered
auditory P1-N1-P2 complex in patients with PD compared to
HCs could be found (16). Significant differences in latency or
amplitude values of the different subcomponents have been
reported between patients with PD and HCs [e.g., (97–101)],
however, no conclusive pattern of auditory alterations emerged.
It is unclear which participant, clinical or ERP related variables
could explain the heterogeneous study results.
Regarding early stage PD, the same inconclusive pattern was
found (79, 99, 100, 102–107). Therefore, no clear alterations in
stimulus-related sound detection in the early stage of PD can
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be assumed based on the current results from auditory oddball
paradigms. However, in the study of Beucke et al. (108), altered
intensity dependence of AEPs (IDAEP) was demonstrated in
early stage PD. A significantly increased IDAEP of the N1/P2
amplitude, indicating low serotonergic activity, was found in
unmedicated patients with PD compared to HCs. This difference
was no longer evident after 12 weeks of dopaminergic treatment
in patients with PD (108). In addition, based on a paired-stimulus
paradigm, Lukhanina et al. (109) and Lukhanina et al. (110)
demonstrated significantly reduced post-excitatory inhibition of
the auditory N1/P2 complex following the second stimulus in
patients with PD evaluated without dopaminergic medication
state compared to HCs. Subgroup analyses based on disease
stage, revealed that diminished post-excitatory auditory cortical
inhibition may be evident at the early stage of the disease
(110). Furthermore, auditory inhibition of the second stimulus
seems to improve after dopaminergic intake in patients with
PD (110).
Mismatch Negativity
The auditory mismatch negativity (MMN) is an ERP associated
with the automatic pre-attentive detection of a deviant auditory
stimulus in a sensory memory trace (85, 111, 112). As such,
the MMN may be considered as a signature of auditory
discrimination abilities (94, 113). The component is classically
obtained with an auditory oddball paradigm in which a deviant
stimulus infrequently occurs in a sequence of standard stimuli.
The deviant stimulus may comprise a change in frequency,
duration, intensity, location, inter-stimulus interval, or the
omission of the stimulus compared to the standard stimulus
(85, 113, 114). The component is very useful in clinical conditions
that require no cooperation of the patient since the MMN can
be elicited in the absence of the participant’s attention (113).
Accordingly, the participant can be asked to perform a visual task,
such as watching a silent-video or reading a book, whilst ignoring
the auditory stimuli, or to focus on stimulus characteristics other
than that of the deviant stimulus during an attentive oddball
paradigm (113, 115, 116). The MMN response is detectable
with a deviant-minus-standard wave and peaks between 100 and
250ms at the frontocentral and central scalp electrodes. Based
on the review by Seer et al. (117) no evidence was found for
altered MMN latency and amplitude values in non-demented
patients with PD compared to HCs. In addition, no effect
of dopaminergic medication on the auditory MMN could be
demonstrated (115, 116).
In most of the studies, the auditory MMN was evaluated
in (subgroups of) patients with early PD (79, 99, 115, 116,
118). Thus, it can be assumed that no deficiencies in automatic
auditory discrimination are present in the early stage of
PD as investigated with a MMN paradigm, irrespective of
the dopaminergic medication status (115). Furthermore, no
significant staging effect on the MMN was found in non-
demented patients with PD in a later study of the same research
group (116). Decreased auditory MMN amplitudes may be
evident when PD is associated with PD dementia and hence,
neurodegeneration is in an advanced stage (116, 118).
Processing Negativity or Nd
In selective attention tasks, attended and unattended auditory
stimuli differ, for example, in location, frequency (i.e., pitch)
or both on which basis the participant may select the task-
relevant stimuli (96, 119, 120). More specifically, the participant
attends one channel in which a deviant stimulus must be detected
in a sequence of standard stimuli whilst ignoring the other
channel (oddball paradigm in a dichotic listening condition)
(119). Generally, the ERPs related to the standard stimuli in
the attended channel are compared to those of the unattended
channel. The negative shift of the ERPs to the attended stimuli
relative to the unattended stimuli has been related to selective
auditory attention and has been identified as the Nd or processing
negativity (PN) (119, 121–123). Based on decreased amplitude
values of the Nd in patients with PD, alterations in selective
auditory attention in PD have been suggested (79, 106, 124).
However, it remains unclear which aspects of selective auditory
attention might be altered in patients with PD, as different results
have been reported regarding the early central subcomponent
(Nd1) and the late frontal subcomponent (Nd2) (16). The Nd1
may reflect the matching process of incoming auditory stimuli
with the internal template, whereas Nd2 is thought to represent
the updating of the internal template (125). Nonetheless, further
research is needed since selective auditory attention has not
yet been investigated sufficiently based on electrophysiological
dichotic listening paradigms. Yet, investigating this aspect of
auditory processing might be highly relevant even more because
alterations of the Nd have been demonstrated in studies in
which early stage PD patients were included (79, 106, 124).
Vieregge et al. (124) evaluated the effect of dopaminergic
medication on the Nd in patients with PD with an average
disease duration of 5.0 years and H&Y stages ranging between
I and III. Compared to HCs, a decreased Nd amplitude was
reported in patients with PD after a 12-hour withdrawal from
dopaminergic medication. Following dopaminergic medication,
the Nd remained unchanged in patients with PD.
N200
The auditory N200 or N2 is a negative wave between 200 and
350ms post stimulus onset that is endogenous in nature (96,
126). Different components of the N2 wave have been described
based on the design of the ERP paradigm and its modality,
namely N2a, anterior N2 (N2b) and posterior N2 (N2c) (85, 126).
An auditory N2a can be elicited by an inattentive auditory
mismatch effect in which case the component is commonly
known as the MMN as described above (85, 126). Regarding
the N2b component, latency and amplitude values have been
defined based on the deviant target stimuli in attentive auditory
oddball paradigms. In this regard, various studies have reported
an increased N2 latency in non-demented patients with PD
compared to HCs [e.g., (97, 101, 127)] although the result was
not always statistically significant and non-differences have also
been demonstrated [e.g., (105, 128)]. Most studies found no
differences in N2 amplitude between patients with PD and HCs
[e.g., (101, 105, 127)]. Yet, a decreased N2 amplitude has been
reported in the studies of Lagopoulos et al. (129), Lagopoulos
et al. (98), and Pekkonen et al. (99) using an auditory oddball
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paradigm. Regarding the N2c component, PD related results are
beyond the scope of the current review since this component has
been specifically considered for the visual modality.
Regarding early stage PD, Broussolle et al. (130) evaluated N2
latency in 8 de-novo patients with PD with an average disease
duration of 1.3 years. Six of these patients had not yet received
dopaminergic medication. N2 latency did not significantly differ
between patients with PD compared to age-matched HCs.
Likewise, the majority of studies reported no abnormalities
regarding N2 latency in patients with early stage PD, neither
without dopaminergic medication (102), nor with dopaminergic
medication (79, 99, 105, 107). Only Philipova et al. (100) found
a prolonged N2 latency in patients with PD compared to HCs,
but only when participants were instructed to provide a motor
response to the presented stimuli and not when they were
required to count the target stimuli. Overall, however, no clear
N2 alterations can be assumed early in disease progression.
P300
The auditory P300 or P3 is a high-level endogenous cognitive
ERP generated by an attentive response to an infrequent deviant
stimulus (131). Usually, the distinction is made between a
parietally maximal P3b component and a frontally maximal P3a
component. The P3b component is elicited after the presentation
of a task-relevant deviant stimulus and may be considered
a signature of auditory categorization based on top-down
voluntary goal-driven attention and working memory processing
(132, 133). In addition, the P3a is elicited by a non-target task-
related or novel distractor stimulus and can be regarded as a
neurophysiological marker of bottom-up involuntary stimulus-
driven attention and the orienting response (134–137). The
auditory P3 component has been classically obtained with a two
(standard, deviant) or three-stimulus (standard, target deviant,
non-target deviant/novel distractor) auditory oddball paradigm
in which the participants are instructed to count the task-relevant
deviant stimuli or to respond by a button-press. The P3 can be
described by the average of the deviant stimuli or a deviant-
minus-standard wave and starts from 250ms at the parietal
and frontal scalp electrodes for the P3b and P3a respectively.
Regarding P3b, the review of Seer et al. (117) concluded that
a prolonged P3b latency may be evident in demented patients
with PD. The authors found no conclusive pattern of P3b
differences in non-demented patients with PD, although P3b
latency was significantly increased in 38% of the related studies.
In addition, it was stated that P3b amplitude was generally
found to be unaltered in demented and non-demented patients
with PD (117). However, it should be noted that regarding the
P3b specifically, both auditory and a smaller amount of visual
oddball paradigms were considered. Regarding P3a, latency and
amplitude findings were rather heterogeneous (117), although a
decreased P3a amplitude seems to be related to disease duration
(116, 117).
Regarding early stage PD, significant differences in latency or
amplitude values of the P3b component have been reported in
patients with PD compared to HCs (100, 103–105, 107, 138).
Overall, however, no clear pattern of P3b alterations emerged
in the early stage of cognitively non-impaired patients with PD
(79, 100, 102–105, 107, 130, 138–141). In addition, no effect
of dopaminergic medication could be shown in the study of
Georgiev et al. (140). In contrast, evidence has been demonstrated
for alterations of the P3a component in early stage patients with
PD compared to HCs (15, 104, 115, 116, 138, 140, 142). In the
study of Cavanagh et al. (142), a trend for an increased P3a
amplitude was found in early stage patients with PD. The authors
suggested that—when filter settings are considered—the altered
P3a amplitude is in line with the study of Solis-Vivanco et al.
(116) in which a decreased P3a amplitude could be demonstrated
in patients with PD compared to HCs. Moreover, a diminished
habituation to novel stimuli over time was found in the PD
group (142). Likewise, alterations of the P3a amplitude were
evident in the study of Pauletti et al. (138). In their study, an
increased P3a latency and decreased P3a amplitude were shown
in PD patients with central fatigue (138). Although no significant
differences in the P3a component were found between patients
with PD and HCs in the study of Solis-Vivanco et al. (15), the
authors suggested that impaired novelty detectionmay be evident
in the early stage of PD based on a reduced phase alignment
for deviant stimuli using time-frequency based analyses (15).
Finally, amplitude alterations of the P3a component seem most
evident when patients with PD are evaluated with dopaminergic
medication (115, 140, 142).
Summary: Electrophysiological
Measurements in PD
A summary of study findings regarding electrophysiological
measurements in early stage patients with PD can be found
in Table 2. Based on various AEPs, neurophysiological
alterations in auditory processing have been demonstrated
in the clinical stage of PD. Considering early stage PD, a
careful selection of electrophysiological paradigms may be
suitable to discriminate patients with early stage PD from
HCs. Study results particularly suggest a pattern of centrally
located ABR abnormalities (wave III–V) in PD. However,
as ABR studies in early stage PD are limited and rather
inconsistent, further research is warranted. Especially because
of the potential involvement of the lower brainstem during
the early stages of PD pathology (75). Furthermore, altered
long latency AEPs in early stage PD may be evident when
ERP paradigms are tailored to evaluate specific and/or more
complex auditory processes. Regarding paired-stimulus
and intensity dependence paradigms, an increased N1/P2
amplitude in early stage patients with PD has been found.
These differences disappeared following initiation with
dopaminergic medication in patients with PD. Regarding
selective attention and three-stimulus oddball paradigms, studies
have shown a decreased Nd amplitude and a decreased or
increased P3a amplitude. Regardless of the direction of the
P3a amplitude alteration, shifts of the P3a component were
most evident when patients with PD were evaluated with
dopaminergic medication.
DISCUSSION
Prodromal markers are defined as indicators of an ongoing
neurodegenerative process in the central or peripheral nervous
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TABLE 2 | Summary of study findings regarding electrophysiological measurements in early stage patients with Parkinson’s disease.
Electrophysiological
measurements
Description Early stage PD
studies
Study findings Effect of
dopaminergic
medication
Strengths/limitations
Short latency AEPs Measurement of auditory
brainstem responses
(28, 79) Non-significant
prolonged IPL I–III, no
difference or prolonged
IPL I–V and wave V
latency
– + Objectivity, standardized
clinical method, established
neural generators, high
specificity
– Inconsistent evidence
Middle latency AEPs Measurement of subcortical
and primary auditory cortex
responses
No early stage PD
studies
– – + Objectivity
– No standardized clinical
method, low sensitivity (most
patients in the clinical PD stage
demonstrate no abnormalities)
Long latency AEPs
i. P1-N1-P2 Measurement of auditory
signal detection
(79, 99, 100, 102–107,
108*, 109, 110*)
Increased IDAEP of the
N1/P2 amplitude
Decreased inhibition of
the N1/P2 amplitude
using a paired-stimulus
paradigm
No clear alterations
using an auditory
oddball paradigm
IDAEP differed no
longer with HCs
Inhibition of the second
stimulus increased
+ Objectivity, information on
distinct auditory (sub-)processes,
direct link to neurotransmission,
correlated with behavioral
outcome measures
– Influence of subject related
variables, such as alertness and
arousal, low sensitivity for
specific ERP components (e.g.,
MMN, N2 and P3b)
ii. MMN Measurement of automatic
pre-attentive auditory
discrimination
(79, 99, 115*, 116*,
118)
No clear alterations No effect was found
iii. Nd/PN Measurement of auditory
selective attention
(79, 106) Decreased Nd
amplitude
–
iv. N2 Measurement of voluntary
auditory discrimination and
categorization
(79, 99, 100, 102, 104,
105, 130)
No clear alterations –
v. P3 Measurement of attentive
auditory categorization
related to (1) bottom-up
involuntary stimulus-driven
attention and the orienting
response (P3a) or to (2)
top-down voluntary
goal-driven attention and
working memory processing
(P3b)
(15, 79, 100, 102–
105, 107, 115, 116,
130, 138, 139, 140*,
141*, 142*)
Evidence for P3a
alterations
No clear
P3b alterations
P3a: Increased P3a
amplitude
P3b: No effect
was found
Study findings indicate the results of electrophysiological measurements in early stage patients with Parkinson’s disease (PD) compared to healthy control participants. Studies
investigating the effect of dopaminergic medication on auditory processing in early stage PD are indicated with an asterisk (*). The main strengths and/or limitations to whether or
not incorporate the electrophysiological measurements into a prodromal auditory marker protocol for PD are given. PD, Parkinson’s disease; AEPs, auditory evoked potentials, IPL,
interpeak latency; IDAEP, intensity dependence of auditory evoked potential; MMN, mismatch negativity; PN, processing negativity.
system prior to the typical symptoms allowing a clinical diagnosis
(143). A prodromal marker can refer to any disease indicator
(1), whether it be of clinical, neuro-imaging, biochemical
or genetic origin. Of critical importance in the utility of
prodromal markers is their sensitivity (the certainty with
which a marker can identify prodromal PD) and specificity
(the ability of a marker to identify disease-free individuals). In
addition, the practicalities and difficulties involved in assessing
a prodromal marker must be considered (10). More specifically,
a prodromal marker should be non-invasive, easy and
relatively inexpensive to administer, sufficiently available, and
reliable (9, 10).
Ideally, studies that aim to define prodromal markers should
be prospective and prodromal markers should be identified
before the patients develop PD (10). Unfortunately, to date,
no prospective studies have assessed the potential of auditory
markers in the prodromal stage of PD. Nevertheless, indirect
evidence for the relevance of auditory markers in prodromal PD
comes from studies in which auditory assessment was carried out
in the early clinical disease stage. At present, multiple studies
have investigated clinically diagnosed patients with early stage
PD (H&Y ≤ II). H&Y stage I and II represent early pathology in
the olfactory bulb and the lower brainstem (75), possibly causing
prodromal symptoms (e.g., olfactory dysfunction, constipation
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and rapid eye-movement sleep behavior disorder) (144). As
such, the earliest pathological disease stages are an important
step in delineating which auditory measurements may be useful
to detect prodromal PD. However, whether audiological or
auditory electrophysiological measurements have the potential to
detect prodromal PD depends on the necessary characteristics
of a biomarker. Overall, auditory alterations in PD can be
evaluated with relatively low-cost and non-invasive audiological
and electrophysiological measurements that are already routinely
available in clinical practice.
Regarding audiological measurements associated with
peripheral auditory processing, pure-tone audiometry revealed
significantly increased middle to high frequency hearing
thresholds in early stage patients with PD compared to HCs.
However, increased pure-tone hearing thresholds are highly
prevalent in the elderly population, which seriously affects
the specificity of hearing thresholds as a marker of prodromal
PD. In addition, pure-tone audiometry is a behavioral test
that relies on a subjective response and requires repeated
responses to provide a reliable outcome. Hence, the potential of
pure-tone audiometry as a marker of prodromal PD is rather
limited. An objective measurement that is generally associated
with peripheral auditory processing involves OAEs. OAEs
are relatively easy to acquire, fast to administer and require
limited cooperation of the participant. Research has found
preliminary evidence for altered OAE response amplitudes in
de-novo patients with PD. Moreover, OAEs have been reported
to be sensitive to dopaminergic medication, which might make
them relevant for monitoring the pharmacological response.
However, older patients, as well as patients with a history of
excessive noise exposure will potentially produce rather weak
OAEs with no measurable responses in the high frequency range.
Hence, OAE measurements in PD comprise both strengths
and shortcomings regarding biomarker perspectives. Therefore,
further research into the sensitivity and specificity of OAE
alterations in prodromal PD is warranted.
The involvement of the peripheral auditory system in PD
has generally been regarded as an age-dependent sensorineural
dysfunction (i.e., presbycusis) (23, 27). Structural changes
underlying presbycusis include loss of cochlear hair cells, which
in turn, affects afferent transmission of auditory information to
higher auditory structures (145). Cochlear hair cells are subject
to feedback control from the olivocochlear efferent system, which
has been proposed to play an important role in preventing
noise-induced and age-related hearing impairment. The auditory
efferent system originates in the brainstem and involves two
major pathways. The LOC efferents provide innervation of the
inner hair cells (IHCs), whereas the MOC efferents primarily
project to the OHCs. Interestingly, dopamine is released from
the LOC efferents and exerts a neuroprotective circuitry for
the cochlea by preventing excitotoxic damage during glutamate
overstimulation (146). In addition, alpha-synuclein has been
located in the cholinergic MOC system (147). By directly
controlling OHC motility and subsequently modulating basilar
membrane motion, the MOC system is proposed to exert a
second efferent pathway preventing hearing impairment. In
sum, peripheral auditory alterations in PD most likely represent
the combined effects of physiological aging processes and the
neuropathological changes intrinsic to PD, which may leave
patients with PD at a higher risk for developing noise-induced,
as well as age-related, hearing impairment. However, the effect of
dopaminergic medication on OAEs cannot be readily explained
by dopaminergic expression at the level of IHCs, as OAEs
mainly represent OHC function. Despite the apparent lack of
dopaminergic terminals in the OHC region, Pisani et al. (23)
suggested that dopamine may exert a modulatory effect on OHCs
via LOC synapses on the MOC efferents. Alternately, De Keyser
et al. (17) argued that abnormal OAEs might result from a
dopamine deficiency at the level of the brainstem.
Audiological measurements associated with central auditory
processing are inherently subjective in nature (66) and, therefore,
have limited potential as a reliable marker for prodromal
PD. In addition, in contrast to peripheral auditory tests, these
measurements are no standardized audiological methods, using a
variety of stimuli and procedures, and differing greatly regarding
task demands. Generally, central auditory processing has been
linked to behavioral phenomena such as sound localization,
auditory discrimination and auditory performance with
competing auditory signals (148). Interestingly, many of these
central auditory processes can be objectively and possibly more
sensitively assessed using electrophysiological measurements.
Auditory electrophysiological measurements are
characterized by a high temporal resolution and provide a
continuous measure of auditory processing, whereas behavioral
measures of central auditory processing reflect the combined
effect of many neural processes (85). Therefore, ERPs have the
ability to demonstrate how auditory processing unfolds over
time and to uncover which distinct neural processes may be
altered in prodromal PD. For example, in contrast to behavioral
measures of selective auditory attention, electrophysiological
registration during dichotic listening tasks may reveal which
specific stages in the process of selective auditory attention
are altered in prodromal PD. Moreover, electrophysiological
measurements meet the necessary practicalities of a biomarker.
At present, electrophysiological studies of auditory processing
in PD have primarily focused on the processing of non-verbal
auditory stimuli using two-stimulus oddball paradigms. Based
on early stage PD studies, auditory ERPs derived from this type
of paradigm (e.g., MMN, N2, and P3b) seem unlikely to detect
prodromal PD. Nevertheless, paradigms that assess specific
and/or more complex auditory processes have demonstrated
differences between early stage patients with PD and HCs. ABR
measurements are well-known in clinical neurological practice
and may be relevant to further investigate the potential early
involvement of the lower brainstem in PD pathology (75).
Nonetheless, bilateral central ABR prolongations have been
reported in a wide variety of neurological conditions (e.g.,
demyelinating diseases, Alzheimer’s disease, schizophrenia)
(74, 149, 150) which may affect the specificity of ABR
measurements as a marker of prodromal PD. Regarding
intensity dependence paradigms, an increased IDAEP of the
N1/P2 component has been found in early stage patients with
PD compared to HCs suggesting lower serotonergic activity and
related depression in PD (108, 151). Interestingly, symptoms of
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depression may occur before the clinical onset of PD (152, 153)
and have already been prospectively established as a prodromal
marker of PD (3). As such, IDAEPs are highly relevant as an
objective indicator for this prodromal marker in PD. Finally,
ERP paradigms that assess the modulation of incoming auditory
stimuli have shown alterations in early stage PD compared
to HCs ranging from automatic pre-attentive to attentive
auditory processing. More specific, pre-attentive auditory gating
abnormalities in early stage PD have been suggested given a
disinhibited N1/P2 component in paired-stimulus paradigms.
At a higher level, Nd and P3a component abnormalities have
been shown using dichotic oddball or attentive three-stimulus
paradigms in early stage PD. Therefore, electrophysiological
measurements focusing on these aspects of auditory processing
may have a potential as a marker for prodromal PD. However,
further research is needed to detect and validate the AEPs that
show abnormalities in the prodromal stage of PD.
The current study results may suggest an involvement
of the central auditory system in early stage PD when
involuntary inhibitory or attentive selective auditory processing
is required. Along the auditory pathway, nuclei of the brainstem
auditory system have been found to exert an inhibitory
function in auditory processing (154). Since PD pathology
especially involves brainstem structures during the early disease
stages (75), inhibitory dysfunction of auditory processing in
early stage PD can be hypothesized. Regarding higher-order
auditory processing, the involvement of a dysfunctional fronto-
striatal circuitry in attentive auditory processing in PD has
been considered. To date, the pathophysiological mechanisms
underlying central auditory processing deficits in PD are
poorly understood and thus, are subject for further research.
Nonetheless, dopamine deficiencies may be related to both
auditory dysfunctions at the brainstem and cortico-subcortical
level. Dopamine has been suggested a neurotransmitter involved
in sensory processing and therefore, may be hypothesized
to have a modulatory role in auditory processing. In the
current review, study results may imply a positive effect of
dopaminergic medication on inhibitory function of repeated
auditory stimuli. In contrast, increased resource allocation for
the unattended channel or novel (distractor) stimuli processing
was suggested in early stage PD. Moreover, alterations of
the P3a component were most evident when patients with
PD were evaluated with dopaminergic medication. Since the
cortico-subcortical circuits are not equally affected by PD
pathology, dopaminergic medication may differentially effect
higher-order cognitive auditory processing (155). Taken together,
dopaminergic medication could modulate both peripheral and
central auditory processing in patients with PD. However, few
studies have directly investigated the effect of dopaminergic
medication on auditory processing in early stage PD.
Overall, the current review provided evidence for auditory
alterations in the early stages of PD. At present, however, the
relevance of auditory markers in prodromal PD is unclear.
In order to truly gain insight into the value of prodromal
auditory markers, prospective studies in large populations or
in selected high-risk groups are needed. The assessment of
auditory processing is already routinely carried out in the
general population and compromises standardized and reliable
measurements, making them highly suitable for prospective
biomarker studies.
CONCLUSION
At present, research has demonstrated altered auditory
processing in early stage PD using audiological and
electrophysiological measurements. Future perspectives for
auditory markers in the prodromal stage of PD can be found in
the use of objective audiological and specific electrophysiological
measurements. However, further research is warranted to assess
the sensitivity and specificity of these auditory measurements
as well as their relationship to other markers of prodromal
PD. Since few studies have directly investigated the effect of
dopaminergic medication on auditory processing in early stage
PD, it is currently unclear whether patients with PD would
benefit from early pharmacological intervention regarding
auditory processing.
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